Dubai Medical University unveils AI innovations in medical education and AI-powered greenhouse
The university introduces the future of medicinal plants and herbal medicine with Doctor Layla, the world's first AI doctor specialising in natural medicine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
7 hours ago
- Zawya
Namibia: The Chinese Embassy Donates Mattresses to Local Hospital
On June 6, the Chinese Embassy in Namibia donated a batch of mattresses to pediatric patients in Gobabis District Hospital. Namibian Officials including Hon. Pijoo Nganate, Governor of Omaheke Region, Hon. Ruth Masake, Deputy Minister of Agriculture, Fisheries, Water and Land Reform, Ms. Tuyakula Haipinge, Executive Director of the Office of the Prime Minister attended the handover ceremony and gave speeches respectively. The Namibian Broadcasting Corporation (NBC) covered the event on the scene. In her speech on behalf of Namibian Prime Minister Rt. Hon. Dr. Elijah Ngurare, Ms. Haipinge expressed sincere gratitude to the Chinese government for its long-term strong support in the areas of health, education, agriculture to Namibia in achieving national objectives. Governor Nganate and Deputy Minister Masake said that the mattresses donated by the Chinese Embassy are very handy for child patients in the hospital to get through winter warmly. On behalf of Ambassador Zhao Weiping, Minister Counselor Shen Jian delivered a speech saying that the sector of health has always been a priority for China's development assistance cooperation with Namibia. During the FOCAC 2024 Beijing Summit, President Xi Jinping announced that China will work with Africa to take Ten Partnership Actions for Modernization, which included the partnership action for health. China is actively implementing relevant achievements and is ready to work with Namibia to strengthen cooperation in the field of health. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Namibia.
Zawya
16 hours ago
- Zawya
XPANCEO partners with the University of Dubai to propel deep tech innovation
Dubai— XPANCEO, a leading deep tech company pioneering the next generation of computing via the development of smart contact lenses, has signed a Memorandum of Understanding (MoU) with the University of Dubai. This strategic partnership underscores a shared commitment to driving innovation at the nexus of academia and industry. Ranked among the UAE's top six academic and corporate organizations by the Nature Index, XPANCEO is on track to unveil the world's first fully integrated smart contact lens by 2026. Its partner, the University of Dubai — established by the Dubai Chamber of Commerce in 1997 — is one of the region's most forward-thinking academic institutions. It is internationally accredited by AACSB and ABET, and is a key player in the UAE's thriving innovation ecosystem. Key areas of collaboration include joint R&D projects and co-authored publications that target high-impact scientific and technological advances. The partnership also includes internship and mentorship programs designed to integrate students into active research settings and provide co-supervision for senior research projects. Both parties will share access to laboratory facilities to support collaborative innovation. They will also organize and participate in conferences, workshops, and expert lectures to facilitate knowledge exchange. Additionally, the partnership will focus on joint involvement in innovation challenges and international hackathons. This partnership reinforces XPANCEO's ongoing commitment to building an ecosystem of visionary thinkers and innovators, while supporting the UAE's broader ambition to become a global innovation hub. 'At XPANCEO, we don't just build breakthrough technologies — we help shape the minds that will define the future. That's why we put a strong focus on cultivating new talent across our core research areas. Our collaboration with the University of Dubai gives students direct access to live challenges in optics, nanomaterials, and bio-integration. They bring curiosity, fresh perspective, and the drive to push science beyond today's limits. We bring deep expertise, infrastructure, and a set of ambitious tasks. This partnership is a hands-on step toward growing local talent and developing the kind of innovation ecosystem that the future demands.' Valentyn Volkov, Co-Founder, Scientific Partner at XPANCEO "As a leading academic institution committed to research-driven innovation, we see this partnership as an opportunity to contribute to the advancement and responsible application of next-generation wearable technologies. This initiative aligns closely with our strategic goals to bridge the gap between academia and industry, foster emerging tech ecosystems in the UAE, and prepare our students to become pioneers of the Fourth Industrial Revolution." Dr. Eesa Al Bastaki, President of the University of Dubai
The National
17 hours ago
- The National
Emirati man with rare blood disorder benefits from new $2 million gene therapy in the US
An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 million gene therapy that eliminates the need for regular blood transfusions. Khalifa Dawood, 22, from Abu Dhabi said he has been given a 'new lease on life' as he recovers from the novel gene treatment he received at Cleveland Clinic Children's hospital in Ohio, which recently won medical approval for the therapy. The UAE has some of the regions highest rates of thalassaemia, also known as sickle cell disease, a condition that limits the body's ability to produce healthy red blood cells. While some carriers show very limited symptoms, others experience bone deformities, shortness of breath, dizziness, organ damage and heart palpitations. The condition can require regular blood transfusions, with research suggesting thalassaemia affects as many as 16.5 per cent of the population. A new treatment used for the first time by the Cleveland Clinic Children's hospital has proven to modify a patient's blood forming cells, and can be delivered as a one-time treatment called Casgevy. Mr Dawood said that he hoped the treatment would allow him to lead a normal life, without the need for regular hospital stays. 'I am hoping this gives me a new lease on life where I am energised to enjoy it,' he said. Life-changing treatment Since its approval by the US Food and Drug Administration in January, the therapy has been delivered to an American woman from Ohio and Mr Dawood. I am hoping this gives me a new lease on life where I am energised to enjoy it Khalifa Dawood Although the treatment is expensive, it is life changing for those who receive it, according to Dr Rabi Hanna, chairman of the paediatric haematology-oncology department at Cleveland Clinic Children's hospital. It is not uncommon for adults to receive specialist care at a children's centre, particularly for conditions they have had since birth, as is the case with Mr Dawood. 'Unlike regular medicines that people take for years, Casgevy is meant to be a one-time treatment that could last a lifetime,' he said. 'It uses CRISPR gene editing, which is a very advanced science. Editing cells safely and precisely takes a lot of time, technology, and testing. 'It is also custom-made, as Casgevy is made from a person's own cells, which are collected, sent to a lab, edited and then returned. That process is complex and individualised.' The innovative treatment uses a gene editing technology called CRISPR/Cas9 to modify a patient's stem cells. The edited cells are then transplanted back into the patient, where they produce more haemoglobin in new healthy red blood cells. The FDA's approval was based on results from a single arm which showed 91 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment. Costly medical care Despite the therapy's success, it is likely to remain out of reach for the majority with costs of about $2.2 million. Gene therapies are typically the most expensive medical treatments. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of haemophilia B, a potentially life threatening disorder that prevents blood from clotting. Priced at about $3.5 million, it was the world's most expensive drug until the arrival of Lenmeldy in March last year. The gene treatment developed by Orchard Therapeutics costs about $4.2 million and is used to treat life threatening nerve disorders in young children. High costs of certain drugs can be covered by insurers, government health systems or charitable foundations when there are no other treatment options. Drug companies also occasionally offer financial support programmes for families in need. The process of administering Casgevy begins by collecting stem cells from the patient's blood that are then sent to the lab to be edited using tiny, precise scissors. By clipping off the DNA responsible for preventing the body making healthy haemoglobin, the repaired cells can then be returned to the body. A course of chemotherapy is then required to clear out the old, sick marrow cells, allowing new healthy ones to grow in their place. Recovery time in the hospital is about four weeks. As the science behind gene editing improves, it should become faster, easier and cheaper to edit cells with higher accuracy, and fewer side effects. 'It is my hope and prediction that price will come down, but I am not sure how quickly,' said Dr Hanna. 'As the science of gene editing improves, it may become faster, easier, and cheaper to edit cells with higher accuracy and fewer side effects. 'Right now, Casgevy is the first gene editing therapy approved for sickle cell and thalassaemia. 'But more companies are developing similar treatments. When that happens, competition can help drive prices down. 'Also as companies learn how to make these therapies at scale, they may reduce production and delivery costs. 'Think of it like early computers or smartphones – they were expensive at first, but prices dropped as technology improved.' Global health drive Although patients like Mr Dawood must travel overseas for expensive gene therapy, the Gulf is also emerging as a go-to destination for emerging treatments. The King Faisal Specialist Hospital & Research Centre in Saudi Arabia is emerging as a leader of regional clinical trials and delivered a breakthrough in haemophilia care, using one-time gene therapy to restore clotting function in eight patients. In the UAE, at Medcare Royal Speciality Hospital Al Qusais, patients are receiving the latest care for rare genetic disorders like spinal muscular atrophy and Duchenne muscular dystrophy, two life-limiting growth conditions. Doctors there said patients were travelling into Dubai from Turkey and elsewhere in the region. Medcare Women and Children Hospital was one of the first private clinics outside the US to administer gene therapy for spinal muscular atrophy, and has since delivered 100 infusions. American Hospital, Al Jalila Children's Hospital and Fakeeh University Hospital also offer gene therapy Zolgensma, which can cost about $2 million per dose. Dr Vivek Mundada, a consultant paediatric neurologist at Medcare Royal Speciality Hospital, said the drug had delivered remarkable outcomes in managing complex genetic conditions. 'Dubai is becoming a centre of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' he said. 'Through our comprehensive, patient-centred care model, we are transforming outcomes for children who previously had limited treatment options.'
